A JAMA Internal Medicine analysis found that federal funding cuts led to termination of 383 NIH‑funded clinical trials between late February and mid‑August, disrupting more than 74,000 enrolled participants. The terminated trials spanned cancer, infectious disease, reproductive health, and other domains, with many trials paused mid‑intervention or follow‑up. Researchers highlighted ethical concerns about abruptly stopping trials that expose participants to risks, interrupt investigational treatments, or leave safety monitoring incomplete. The analysis documented the scale and diversity of affected studies and raised questions about downstream loss of scientific value and participant trust. The reporting and related analyses have prompted scrutiny of NIH decision‑making and calls for clearer processes to mitigate patient and scientific harm when funding priorities shift.